Chemotherapy Kidney Damage: Potential Antidote Found
- A recent study by Mass General Brigham investigators suggests that glucarpidase, an FDA-approved medication, could be a key antidote for kidney toxicity in patients undergoing chemotherapy with methotrexate...
- The study revealed that patients treated with glucarpidase, which rapidly eliminates MTX from the bloodstream, had significantly improved kidney recovery rates compared to those who did not receive...
- Glucarpidase's ability to quickly convert MTX into inactive metabolites has long been recognized.
discover how glucarpidase, an FDA-approved medication, is offering hope against chemotherapy-induced kidney damage.A groundbreaking study analyzing data from major U.S. cancer centers reveals that patients treated with glucarpidase experienced substantially improved kidney recovery. Glucarpidase swiftly removes methotrexate (MTX) from the bloodstream, potentially mitigating the severe complications associated with this chemotherapy drug. This study, published in Blood, provides crucial clinical evidence, offering new insights for clinicians. The findings, which show a 2.7-fold increase in kidney recovery rates, will hopefully encourage wider adoption. News Directory 3 has the full scoop. This could change the way we treat chemotherapy side effects. Discover what’s next …
Glucarpidase offers Hope against Kidney Toxicity After Chemotherapy
A recent study by Mass General Brigham investigators suggests that glucarpidase, an FDA-approved medication, could be a key antidote for kidney toxicity in patients undergoing chemotherapy with methotrexate (MTX). The research, which analyzed data from 28 major U.S. cancer centers, focused on the link between glucarpidase treatment and outcomes for patients with MTX-induced acute kidney injury (AKI). The findings appear in Blood.
The study revealed that patients treated with glucarpidase, which rapidly eliminates MTX from the bloodstream, had significantly improved kidney recovery rates compared to those who did not receive the treatment. MTX, while effective against cancers involving the central nervous system, can cause severe complications like AKI, liver toxicity, and neutropenia, especially at high doses.
Glucarpidase’s ability to quickly convert MTX into inactive metabolites has long been recognized. Though, this study provides crucial evidence of its clinical benefits, addressing a critically important gap in understanding and potentially reducing the variation in its use.
Researchers emulated a randomized clinical trial using data collected between 2000 and 2022 from 708 patients with MTX-induced AKI. Of thes,209 received glucarpidase within four days of MTX exposure,while 499 did not. Kidney recovery was assessed by monitoring changes in serum creatinine levels at hospital discharge.
The analysis showed a 2.7-fold increase in kidney recovery among patients receiving glucarpidase. These patients also experienced faster recovery and a reduced risk of severe neutropenia or liver toxicity.
Shruti Gupta, an associate physician at Brigham and Women’s Hospital and director of Onconephrology at BWH and Dana-Farber Cancer Institute, emphasized the uniqueness of glucarpidase as one of the few potential antidotes for chemotherapy-induced toxicity. “Even though glucarpidase was approved by the FDA in 2012, our study is the first to provide a complete assessment of its potential clinical benefits,” gupta said.
David E. Leaf, director of clinical and translational research in acute kidney injury at BWH, highlighted the rigor of their research approach. “Target trial emulation is a way to effectively analyze real-world data and to draw causal inferences from it, especially when clinical trials are unavailable and would be impractical to perform,” Leaf said.
Leaf hopes the findings will encourage wider adoption of glucarpidase for patients experiencing kidney toxicity from MTX. “FDA approval is only the first step. If people aren’t using the drug, then patients aren’t benefiting from it,” he said. “Our findings offer clinicians evidence-based data supporting glucarpidase.”
What’s next
the research team anticipates further studies to refine glucarpidase’s submission and identify specific patient populations that would benefit most from this targeted intervention for kidney toxicity.